In summary, the rapid co-development of new therapeutic strategies that are integrated with genetic, transcriptional, pathologic, and circulating biomarkers—augmented by AI and ML tools—will probably redefine the way we manage KRAS G12C-mutant cancers, enabling personalized selection, early response assessment, and adaptive therapeutic strategies. Here, KRAS is linked to cancer.